HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ('China Sky One Medical' or 'the Company') (Amex: CSY), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ('PRC'), announced today that it successfully developed 26 new drugs that are currently in clinical trials.

Heilongjiang Tianlong Pharmaceutical, Inc. ('Tianlong'), a wholly-owned subsidiary of China Sky One Medical, recently completed research and development for the 26 new drugs, which have been submitted to the State Food and Drug Administration (SFDA) in the PRC for approval.

    -- Four drugs, including Cleaning suppositories, Tinidazole
       suppositories, Policresulen vaginal suppositories, and Aciclover gel
       are for the treatment of vaginits;
    -- Three drugs, including Chlorhexidine Gluconate, Cetylpyridinium
       Chloride and Compound Chlorhexidine, are gargles for the treatment
       of toothache;
    -- Three drugs, including Diclofenac Sodium Suppositories, Paediatric
       Ibuprofen suppositories and Musky cream, are for pain relief;
    -- Three drugs, including Hydroxybenzene gel, Podophyllotoxin Tincture
       and Nitrofurantoin suppositories, are anti-infectives;
    -- Two drugs, including Collunarium and Compound Naphazoline Spray, are
       for the treatment of rhinopathy;
    -- Two drugs, including Sulfasalazine suppositories and Sodium ferulate
       injection are for the treatment of cardiovascular disease;
    -- Methionine Vitamin B1 injection is for improving liver function;
    -- Doxofylline injection is for the treatment of asthma;
    -- Pantoprazole sodium injection is for the treatment of canker sores;
    -- Calcium Folinate injection is intended as an antidote for folic acid
       deficiency;
    -- Hydrastis suppositories are for the treatment of colds; and
    -- The final four drugs, including hemorrhoids gel, hemorrhoids liquids,
       chilblain cream and expectorant, are all externally used.

'We are excited about the potential for our new drugs currently in clinical trials and we believe that our advanced R&D capabilities will continue to help us expand our market share,' said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. 'We estimate that the new drugs will account for a 30% increase in our 2009 revenues if production approval is received by the end of the year.'

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products.